Bristol Myers Squibb gets European Commission nod for Opdivo in combo with cisplatin, gemcitabine for urothelial carcinoma Ruchika Sharma30 May 2024 12:49 PM ISTPrinceton: Bristol Myers Squibb has announced that the European Commission (EC) has approved Opdivo (nivolumab) in combination with...
EMA Committee recommends nod for Bristol Myers Squibb Opdivo in combination with Cisplatin, Gemcitabine for Urothelial Carcinoma Ruchika Sharma28 April 2024 11:30 AM ISTPrinceton: Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...
USFDA approves Opdivo in combo with Cisplatin and Gemcitabine for first-line treatment of adult patients with metastatic Urothelial Carcinoma: Bristol Myers Squibb Ruchika Sharma9 March 2024 1:30 PM ISTPrinceton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) approved Opdivo (nivolumab), in combination...
USFDA accepts for priority review Bristol Myers Squibb application for Opdivo plus Cisplatin-Based Chemotherapy for urothelial carcinoma Ruchika Sharma7 Dec 2023 12:30 PM ISTPrinceton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License...
Bristol Myers Squibb Opdivo in combo with cisplatin based chemotherapy gets EMA validation for Urothelial Carcinoma Ruchika Sharma31 Oct 2023 12:30 PM ISTPrinceton: Bristol Myers Squibb has announced that the European Medicines Agency (EMA) has validated its type II variation application for...
Perioperative regimen of neoadjuvant Opdivo, chemotherapy improves event free survival in Resectable Non-Small Cell Lung Cancer: Bristol Myers Squibb Ruchika Sharma25 Sept 2023 1:30 PM ISTPrinceton: Bristol Myers Squibb has announced the Phase 3 CheckMate -77T trial has met its primary endpoint of improved event-free survival...
Bristol Myers Squibb gets European Commission nod for Opdivo as adjuvant treatment for patients with completely Resected Stage IIB or IIC Melanoma Ruchika Sharma23 Aug 2023 11:23 AM ISTPrinceton: Bristol Myers Squibb has announced that the European Commission (EC) has approved Opdivo (nivolumab) as a monotherapy for the...
Bristol Myers Squibb gets positive CHMP opinion recommending nod for Opdivo for adjuvant treatment for Melanoma Ruchika Sharma24 July 2023 11:22 AM ISTPrinceton: Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency...
Bristol Myers Squibb receives EMA panel recommendation for approval of Opdivo with chemotherapy for lung cancer patients Ruchika Sharma29 May 2023 11:30 AM ISTOpdivo is a programmed death-1 immune checkpoint inhibitor that is designed to uniquely harness the body's own immune system to help restore...
Giovanni Caforio to retire as Bristol Myers Squibb CEO Ruchika Sharma30 April 2023 1:30 PM ISTNew York: Bristol Myers Squibb has announced that Giovanni Caforio, MD, Chairman of the Board and Chief Executive Officer, has decided to retire...
USFDA accepts Bristol Myers Squibb sBLA for Opdivo for Resected Stage IIB/C Melanoma Ruchika Sharma4 March 2023 10:00 AM ISTMelanoma is a form of skin cancer characterized by the uncontrolled growth of pigment-producing cells (melanocytes) located in the skin.
Setback: Bristol Myers drug combo fails to meet main goal in kidney cancer trial Ruchika Sharma30 July 2022 1:15 PM ISTRenal cell carcinoma (RCC) is the most common type of kidney cancer in adults
